Keywords: Novartis, Galvus, Type 2 diabetes, European Commission

EU approval for added use of Novartis diabetes drug Galvus

Article | 06 December 2011

Print This

The European Commission has approved Swiss drug major Novartis’ (NOVN: VX) Galvus (vildagliptin) (50mg once a day) for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in